---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028003"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:57:42.702878+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q2 revenue up 29% YoY to $38.5M; net loss widens to $47.7M, maintains 2022 outlook

## Summary
- Software revenue $30.0M (+25% YoY); drug discovery revenue $8.5M (+48% YoY).
- Net loss of $47.7M vs. $35.0M in Q2 2021; gross profit $17.1M (+43%).
- Cash, equivalents, and marketable securities ~$513M, down from $529M at March 31, 2022.
- IND for MALT1 inhibitor SGR-1505 cleared; Phase 1 trial in B-cell lymphoma expected Q4 2022.
- Maintains full-year 2022 guidance: total revenue $161M–$181M, software revenue $126M–$136M.

## SEC filing metadata
- accession: 0001564590-22-028003
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000156459022028003/0001564590-22-028003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000156459022028003/sdgr-8k_20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028003
- JSON: https://secwatch.observer/filing/0001564590-22-028003.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.